Details of the Drug Combination

General Information of Drug Combination (ID: DCD5CIT)

Drug Combination Name

Cabazitaxel JNK-IN-8

Indication

Disease Entry	Status	REF
Minimally invasive lung adenocarcinoma	Investigative	[1]

Component Drugs

Cabazitaxel DMPAZHC

JNK-IN-8 DMLWYJB

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: NCI-H322M

Zero Interaction Potency (ZIP) Score: 4.69

Bliss Independence Score: 5.43

Loewe Additivity Score: 5.21

LHighest Single Agent (HSA) Score: 10.17

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Cabazitaxel

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Metastatic prostate carcinoma	N.A.	Investigative	[3]

Cabazitaxel Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[5]
------------------------------------------------------------------------------------

Cabazitaxel Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[6]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[6]
------------------------------------------------------------------------------------

Cabazitaxel Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Forkhead box protein O3 (FOXO3)	OTHXQG4P	FOXO3_HUMAN	Affects Expression	[7]
Proline-rich AKT1 substrate 1 (AKT1S1)	OT4JHN4Y	AKTS1_HUMAN	Decreases Expression	[7]
------------------------------------------------------------------------------------

Indication(s) of JNK-IN-8

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[4]

JNK-IN-8 Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Stress-activated protein kinase JNK3 (JNK3)	TT056SO	MK10_HUMAN	Inhibitor	[4]
JNK2 messenger RNA (JNK2 mRNA)	TT3IVG2	MK09_HUMAN	Inhibitor	[4]
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

JNK-IN-8 Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cell division cycle and apoptosis regulator protein 1 (CCAR1)	OTUXLQZZ	CCAR1_HUMAN	Increases Expression	[8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCSJYRS	DU-145	Investigative	[1]
Adenocarcinoma	DCNXMJU	A549	Investigative	[1]
Adenocarcinoma	DC5AFQ5	HCC-2998	Investigative	[1]
Adenocarcinoma	DCJH2E0	HCT-15	Investigative	[1]
Adenocarcinoma	DC3NKY4	HCT116	Investigative	[1]
Adenocarcinoma	DCUZ6F8	HT29	Investigative	[1]
Adult acute myeloid leukemia	DC72DKY	HL-60(TB)	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCN7O8T	MOLT-4	Investigative	[1]
Anaplastic large cell lymphoma	DC61GXS	SR	Investigative	[1]
Astrocytoma	DCSRSU9	SNB-19	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DC9M25H	CCRF-CEM	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCOIQA9	NCI\\/ADR-RES	Investigative	[1]
Large cell lung carcinoma	DC84H27	NCI-H460	Investigative	[1]
Lung adenocarcinoma	DCF7B7I	NCI-H522	Investigative	[1]
Non-small cell lung carcinoma	DCSQEOL	HOP-92	Investigative	[1]
Prostate carcinoma	DCP3KRB	PC-3	Investigative	[1]
Renal cell carcinoma	DC3SF5P	SN12C	Investigative	[1]
Carcinoma	DCMOWN3	RXF 393	Investigative	[9]
Colon carcinoma	DC7PUL6	KM12	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 19 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
3	Cabazitaxel FDA Label
4	Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
5	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
7	The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
8	A H2AX?CARP-1 Interaction Regulates Apoptosis Signaling Following DNA Damage. Cancers (Basel). 2019 Feb 14;11(2):221. doi: 10.3390/cancers11020221.
9	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.